4-Methylumbelliferone (4-MU)

Name: 4-Methylumbelliferone (4-MU)
Brand: Selleck Chemicals
SKU: S2256
Rating: 5 (2 reviews)

For research use only.

Catalog No.S2256

2 publications

4-Methylumbelliferone (4-MU) Chemical Structure

CAS No. 90-33-5

4-Methylumbelliferone is a hyaluronic acid (HA) synthesis inhibitor with an IC50 of 0.4 mM.

Selleck's 4-Methylumbelliferone (4-MU) has been cited by 2 publications

Mol Carcinog, 2019, 58(3):321-333

PubMed: 30365189 ( click the link to review the publication )

J Med Virol, 2019, 91(8):1440-1447

PubMed: 30900754 ( click the link to review the publication )

Purity & Quality Control

Biological Activity

Description

4-Methylumbelliferone is a hyaluronic acid (HA) synthesis inhibitor with an IC50 of 0.4 mM.

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
COS1 cells	NWnpS3R[TnWwY4Tpc44h[XO\|YYm=			MlKzRYdwdmm\|dHnjJIFkfGm4aYT5JJdieyCmZYTldo1qdmWmIHnuJGNQWzFiY3XscJMhfHKjboPm[YN1\WRid3n0bEBISUxiND3QVGFTKGejbX3hJJJm[2WydH;yMEBGSzVyPUCuNFIyKM7:TR?=	NFPsWHoyOjZzN{myOC=>
CV-1 cells	NWKzSXR2TnWwY4Tpc44h[XO\|YYm=			NUfkfYZxVWG6aX3hcEBz\XCxcoTldkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDldo95cXOxbXWgdJJwdGmoZYLheI9zKGGldHn2ZZRm\CC{ZXPldJRweiCpYX3tZUBI[Wx2IHPobY1memmlIHnuJJRz[W6\|aXXueIx6KHS{YX7z[oVkfGWmIFPWMVEh[2WubIOgZpkh\nWwY4Tpc45idCCjc4PhfUwhTUN3ME2wMlA1OyEQvF2=	NXPifpptOTF5MkC4OVQ>
COS-1 cells	NEjLNZdHfW6ldHnvckBie3OjeR?=			M1mzcWlvKH[rdILvJJRz[W6\|YXP0bZZifGmxbjDv[kBpfW2jbjDw[ZJwgGm\|b33lJJBzd2yrZnXyZZRweiCjY4TpeoF1\WRicnXj[ZB1d3JiZ3HtcYEhdWWjc4Xy[YQhcW5iUGDBVk1ISUx2IHPobY1memmlIFPPV{0yKGOnbHzzMEBGSzVyPUCuNFIh\|ryP	M33uc\|EzQDd\|NUG3
CV-1 cells	NILyO3BHfW6ldHnvckBie3OjeR?=			MoXyRYN1cX[jdHnvckBw\iCyZYLvfIl{d22nIIDyc4xq\mW{YYTvdkBi[3SrdnH0[YQhemWlZYD0c5Ih\2GvbXGgcYVie3W{ZXSgZpkhcW6mdXP0bY9vKG:oIEWwKUBw\iCvYYjpcZVuKGGua3HsbY5mKHCqb4PwbIF1[XOnIHHjeIl3cXS7LDD0doFve2[nY4Tpc44h[XO\|YYmgbY4hS1ZvMTDj[YxteyxiRVO1NF0xNjB6OUGzJO69VQ>?	Mkm0PVg{PjZ{MB?=
CV-1 cells	NVTFdXVITnWwY4Tpc44h[XO\|YYm=			NX\qW2RSUW5idnn0do8hfHKjboPjdolxfGmxbnHsJIFkfGm4YYTpc44hd2ZiUHXyc5hqe2:vZTDwdo9tcW[ncnH0c5Ih[WO2aY\heIVlKHKnY3XweI9zKGejbX3hJEhRWEGUKTDlfJBz\XO\|ZXSgbY4hS1ZvMTDj[YxteyxiRVO1NF0xNjB4IN88US=>	MVW4OVc3QTB5
COS-1 cells	M173fGZ2dmO2aX;uJIF{e2G7			NEftbJVKdiC4aYTyc{Bi\2:waYP0JIFkfGm4aYT5JJRme3SnZDDmc5IhfHKjboPhZ5RqfmG2aX;uJIlvKGi3bXHuJHBRSVJiZ3HtcYEuT2GuNDDjbIlu\XKrYzDDU3MuOSClZXzsd{whTUN3ME2wMlAzKM7:TR?=	NYm5WG1WOTJ5Mkm2Olg>
CV-1 cells	NV7JcWU{TnWwY4Tpc44h[XO\|YYm=			NYnS[WpIUW5idnn0do8h\X[jbIXheIlwdiCjZ3HpcpN1KFK[Uj3hcJBp[S:SUFHSMYdidW2jIHnuJGNXNTFiY3XscJMh[nliY3;0doFve2[nY4Tpc44h[XO\|YYmge4F{KGSndHXycYlv\WRuIFXDOVA:OC5\|MkWg{txO	NWHWN3VWOTJ7NUSwOlE>
HepG2 cells	Mmn5SpVv[3Srb36gZZN{[Xl?			NVPocWFZTW[oZXP0bZZmKGOxbnPlcpRz[XSrb36gZYdicW6\|dDDoeY1idiCSUFHS[4FudWFiZYjwdoV{e2WmIHnuJGhmeEd{IHPlcIx{NCCHQ{WwQVAvODN7IN88US=>	M{DPbFE3OTB5MUWw
Huh7 cells	NGjqTmlHfW6ldHnvckBie3OjeR?=			M1zVeGZ2dmO2aX;uZYwh[WO2aY\peJkh[XRiaIXtZY4hWFCDUjDnZY1u[SCrbjDIeYg4KGOnbHzzJIJ6KHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OD1yLkKyJO69VQ>?	NULoeW5yOTZ\|Nk[2NFE>
Huh7 cells	MXHGeY5kfGmxbjDhd5NigQ>?			NX76[4x2TW[oZXP0JI9vKFCSQWKg[4FudWFidILhcpNi[3SrdnH0bY9vKGGldHn2bZR6KGmwIFj1bFch[2WubIOsJGVEPTB;MD6yNkDPxE1?	NF2wdmcyPjR3MUC4Oy=>
U2OS cells	M1\1[GZ2dmO2aX;uJIF{e2G7			NHvyZ\|ZG\m[nY4Sgc44hWFCDUnfhcY1iKHS{YX7zZYN1cX[jdHnvckBi[3Srdnn0fUBqdiCXMl;TJINmdGy\|LDDFR\|UxRTBwMEOg{txO	NIfzZoMyPjNyMEm0OC=>
CV1 cells	NWX0NmRwTnWwY4Tpc44h[XO\|YYm=			MmTpWJJidnOjY4TpeoF1cW:wIH;mJHBRSVKpYX3tZUBqdiCFVkGgZ4VtdHNuIFXDOVA:OC5yN{[g{txO	MYCxOlgzOTd4OR?=
human keratinocytes	NVrJXZVQWHKxbHnm[ZJifGmxbjDhd5NigQ>?			MmLWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCtZYLheIlvd2O7dHXzMEBGSzVyPUig{txO	M{PGV\|E3QDJzN{[5
HT29 cell	M374[XBzd2yrZnXyZZRqd25iYYPzZZk>			NH;HSGZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUNlkh[2WubDDsbY5mNCCHQ{WwQVQ2KM7:TR?=	NHvkdmoyPjh{MUe2PS=>
NIH3T3 cells	MVvGeY5kfGmxbjDhd5NigQ>?			NFnWZolC[3Srdnn0fUBifCCqdX3hckBRWEGUIHfhcY1iKHS{YX7z[oVkfGWmIHnuJG5KUDOWMzDj[YxteyCkeTDseYNq\mW{YYPlJIFkfGm4aYT5JIF{e2G7LDDFR\|UxRTBwM{Kg{txO	NHTJV40yPjh3NEC4OS=>
CV1 cells	NWPQdlI{TnWwY4Tpc44h[XO\|YYm=			NWWwcnRPXHKjboPhZ5RqfmG2aX;uJI9nKGi3bXHuJHBRSVKpYX3tZUBqdiCFVkGgZ4VtdHNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvOzB6IN88US=>	MVixOlk4ODN7MR?=
Huh7 cells	Mn;KSpVv[3Srb36gZZN{[Xl?			NFfvTGJC[3Srdnn0fUBifCCqdX3hckBRWEGUIHfhcY1iKGmwIFj1bFch[2WubIOgZpkhfHKjboPhZ5RqfmG2aX;uJIF{e2G7LDDFR\|UxRTBwMkKg{txO	MVuxO\|A{PDF2OR?=
HepG2 cells	MU\GeY5kfGmxbjDhd5NigQ>?			NX;WZW0zSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUIHfhcY1iKGmwIHGgTIVxTzJiY3XscJMh[nliUGDBVk1ISUx2IITyZY5{[WO2aY\heIlwdiCjc4PhfUwhTUN3ME2wMlE2QCEQvF2=	NXL6PYZsOTZ7N{OzOVg>
HepG2 cells	NVn6U2lxTnWwY4Tpc44h[XO\|YYm=			NFnGUVNC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHBRSVJiZ3HtcYEhcW5iSHXwS\|Ih[2WubIOgZpkhWFCDUj3HRWw1KHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OD1yLkG1PO69VQ>?	M4rzblE3QTd7M{Sx
CV1 cells	NELOSWdHfW6ldHnvckBie3OjeR?=			NIW1dGxC[3Srdnn0fUBifCCqdX3hckBRWEGUZ3HtcYEhcW5iQ2[xJINmdGy\|LDDFR\|UxRTBwM{C4JO69VQ>?	M120flE4ODB3M{m0
HEK293 cells	NUHyc5hjTnWwY4Tpc44h[XO\|YYm=			NIDlOodC[3Srdnn0fUBifCCqdX3hckBi\Gmyb4PlJJRqe3O3ZTDQVGFTKGejbX3hJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZpkhWFCDUj3HRWw1KHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OD1yLkOxJO69VQ>?	NGLp[20yPzN2M{O3NS=>
rat L6 cells	MnnqSpVv[3Srb36gZZN{[Xl?			NIHMUYlG\m[nY4Sgc44h\mG2dImgZYNq\CCxeHnkZZRqd25iaX6gdoF1KEx4IHPlcIx{NCCHQ{WwQVUh\|ryP	MYCxO\|M1OzN5MR?=
HepG2 cells	NFr4R5lHfW6ldHnvckBie3OjeR?=			MYLB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYTDpckBJ\XCJMjDj[YxteyCkeTDQVGFTNUeDTESgeJJidnOjY4TpeoF1cW:wIHHzd4F6NCCHQ{WwQVAvODh{IN88US=>	NYXoNIZVOTdzNUewNVk>
CV1 cells	NXHROnNtTnWwY4Tpc44h[XO\|YYm=			MoTPRYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDQVGFT[WyyaHGgbY4hS1ZzIHPlcIx{KGK7IFfBUFQhfHKjboPhZ5RqfmG2aX;uJIF{e2G7IHHmeIVzKDJ2IHjyd{whTUN3ME2zMlQ3KM7:TR?=	NUPtbWFjOTd3MEeyNlU>
CV1 cells	NEXDVGJHfW6ldHnvckBie3OjeR?=			M{C4PGFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hJIlvKEOYMTDj[YxteyCkeTDHRWw1KHS{YX7zZYN1cX[jdHnvckBie3OjeTDh[pRmeiB{NDDodpMtKEWFNUC9NE4xOyEQvF2=	NVXQVXAzOTd3MEeyNlU>
CV1 cells	M1HGTGZ2dmO2aX;uJIF{e2G7			NYX4S4pySWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUZ3HtcYEh\XiycnXzd4VlKGmwIFPWNUBk\WyuczDifUBz\WOncITvdkB1emGwc3HjeIl3[XSrb36gZZN{[XluIFXDOVA:OC5\|MEig{txO	M1PGU\|E5ODJ7MUe4
CV1 cells	NUfxTJhITnWwY4Tpc44h[XO\|YYm=			MnTWRYdwdmm\|dDDhZ5Rqfmm2eTDheEBRWEGUZ3HtcYEhcW5iQ2[xJINmdGy\|IHL5JJRz[W6\|YXP0bZZifGmxbjDhd5NigSxiRVO1NF0xNjNyODFOwG0>	MVGxO\|EzQTd{NR?=
HEK293 cells	NUDnTFF1TnWwY4Tpc44h[XO\|YYm=			M1LlWGFod26rc4SgZYN1cX[rdImgZZQhWFCDUnfhcY1iKHKnY3XweI9zKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[nliR1HMOEB1emGwc3HjeIl3[XSrb36gZZN{[XluIFXDOVA:OC5yM{Wg{txO	NXTpfXJ3OTd{OUK2NFY>
NIH3T3 cells	MmXhSpVv[3Srb36gZZN{[Xl?			M2OzbGFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hJIV5eHKnc4Pl[EBqdiCQSVizWFMh[2WubIOgZpkhT0GONDD0doFve2GldHn2ZZRqd25iYYPzZZktKEWFNUC9NE4{OiEQvF2=	MoHUNVc3OjR5N{e=
HEK293 cells	NWXiVIV7TnWwY4Tpc44h[XO\|YYm=			NHf5OHdC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{KGK7IFfBUFQhfHKjboPhZ5RqfmG2aX;uJIF{e2G7LDDFR\|UxRTBwMUmg{txO	NH[wfpIyQDB{OUG3Oi=>
HEK293 cells	NYjtbJc4TnWwY4Tpc44h[XO\|YYm=			MUTB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIF{e2W\|c3XkJIF{KGGSMjDn[Y5mKGmwZIXjeIlwdixiRVO1NF0xNjF{IN88US=>	M3nYPVE5ODJ7MUe2
HEK293 cells	NUXLUVhxTnWwY4Tpc44h[XO\|YYm=			MV7B[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBqdiCKRVuyPVMh[2WubIOgZpkhT0GONDD0doFve2GldHn2ZZRqd25iYYPzZZktKEWFNUC9NE4xPDVizszN	NUXxZ2txOTh{OUG2OFU>
HepG2 cells	NWn4R4NTTnWwY4Tpc44h[XO\|YYm=			NFLvdmRC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHBRSVKjbIDoZUBtcWejbnSgZolv\GmwZzDkc41icW5iZYjwdoV{e2WmIHnuJIh2dWGwIFjldGczKGOnbHzzJINwNXS{YX7z[oVkfGWmIIfpeIghT2GuNDDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5yM{mg{txO	NGHRO4cyQDh\|NUexPS=>
RAW264.7 cells	NHTCOplHfW6ldHnvckBie3OjeR?=			MVjTeZBxemW\|c3nvckBw\iCOUGOvTWZPNWejbX3hMZN1cW23bHH0[YQhVk9icILv[JVkfGmxbjDpckBud3W\|ZTDSRXczPjRwNzDj[YxteyxiRVO1NF0yPy53IN88US=>	M3TlcVE5QDB7M{K1
BL21 cells	Mlz1SpVv[3Srb36gZZN{[Xl?			MnvnSIl{eGyjY3Xt[Y51KG:oIILh[IlwKGyjYnXs[YQhOiiVKT2oNk1j\W68b4nsMZBp\W67bHHtbY5wMS1\|LYu0MXsyNDFvZHn0dol1cW9vMj2oOU1u\XSqeXytNk1xcGWweXytc5higm:uLUStfYwqNWW2aH;4fX0ueGinbonsgU1xem:yaX;ubYMh[WOrZDDmdo9uKEeVVD3meZNm\CCqdX3hckBRWEGUZ3HtcYEh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDifUB{[2mwdHnscIF1cW:wIIDyc5hqdWm2eTDhd5NigSxiRVO1NF0xNjR3IN88US=>	NIi3VGMyQTN2OUG3Oi=>
BHK21 cells	M{TCbmZ2dmO2aX;uJIF{e2G7			MX;B[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYTDlfJBz\XO\|ZXSgbY4hSkiNMkGgZ4VtdHNiYYPz[ZN{\WRiYYOgV2VCWCCjY4Tpeol1gSCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJJRz[W6\|YXP0bZZifGmxbjDhd5NigSxiRVO1NF0xNjR3IN88US=>	NH\ZUngyQTN2OUG3Oi=>
HepG2/C3A cells	M{PnfmZ2dmO2aX;uJIF{e2G7			M3TwdWFkfGm4YYTpc44hd2ZiaIXtZY4hWFCDUnfhcY1iKGyrZ3Hu[EBjcW6maX7nJIRwdWGrbj3t[YRq[XSnZDD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHliaX6gbJVu[W5iSHXwS\|IwSzODIHPlcIx{KGOxLYTyZY5{\mWldHXkJJdqfGhiZoXz[YQhT2GuND3MRmQh[nliY3;0doFve2[nY4Tpc44h[XO\|YYmsJGVEPTB;MD6wNFM5KM7:TR?=	NHXlWZEyPzRyM{[4PC=>
HepG2 cells	NVrhTlJ1TnWwY4Tpc44h[XO\|YYm=			Mn\xRYdwdmm\|dDDhZ5Rqfmm2eTDheEBRWEGUZ3HtcYEh\XiycnXzd4VlKGmwIHj1cYFvKEincFeyJINmdGy\|IHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iC{ZXPldJRweiC2cnHud4FkfGm4YYTpc44h[nlicnXwc5J1\XJiZ3Xu[UBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;sMEBGSzVyPUCuNFUh\|ryP	NGfVVIIyQDZ{NUW1PS=>
COS1 cells	MmWxSpVv[3Srb36gZZN{[Xl?			MUDB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIILlZ49u[mmwYX70JHBRSVKpYX3tZUBmgHC{ZYPz[YQhcW5iQ1;TNUBk\WyuczDjc{1mgHC{ZYPzbY5oKEeDTESgZZN{\XO\|ZXSgZZMhfHKjboPjdolxfGmxbnHsJIFkfGm4aYT5JIFnfGW{IES4JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE4xOiEQvF2=	MWqxPVUxPzh4MR?=
HepG2 cells	NHzmWFdHfW6ldHnvckBie3OjeR?=			MkXlRYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDQVGFT\2GvbXGg[ZhxemW\|c3XkJIlvKEincFeyJINmdGy\|IHL5JGdCVDRidILhcpNi[3SrdnH0bY9vKGG\|c3H5MEBGSzVyPUCuNlI{KM7:TR?=	M{OwNVE5Ozl2OUC3
CV1 cells	NH3L[nJHfW6ldHnvckBie3OjeR?=			Mn3iRYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDQVGFT\2GvbXGgcIlo[W6mIHLpcoRqdmdiZH;tZYlvKGW6cILld5Nm\CCrbjDh[pJq[2GwIHfy[YVvKG2xbnvlfUBEXjFiY3XscJMh[29vdILhcpNn\WO2ZXSge4l1cCCodYPl[EBI[Wx2LVTCSEBjgSC2cnHud4FkfGm4YYTpc44h[XO\|YYmsJGVEPTB;MD6wN\|Mh\|ryP	NHPjO4QyQDh{NkKwOS=>
CV1 cells	MojnSpVv[3Srb36gZZN{[Xl?			MlHhRYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDQVGFT[WyyaHGgcIlo[W6mIHLpcoRqdmdiZH;tZYlvKGW6cILld5Nm\CCrbjDh[pJq[2GwIHfy[YVvKG2xbnvlfUBEXjFiY3XscJMh[29vdILhcpNn\WO2ZXSge4l1cCCodYPl[EBI[Wx2LVTCSEBjgSC2cnHud4FkfGm4YYTpc44h[XO\|YYmsJGVEPTB;Mz60OkDPxE1?	M4XCd\|E5QDJ4MkC1
U2OS cells	MmLCSpVv[3Srb36gZZN{[Xl?			NIP1c4lC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHBRSVKpYX3tZUBqdiCXMl;TJINmdGy\|IHL5JJRz[W6\|YXP0bZZifGmxbjDhd5NigSxiRVO1NF0xNjB{IN88US=>	NXrBU2NpOTh\|Mkm3OVE>
Hep G2 cells	M{DJcGZ2dmO2aX;uJIF{e2G7			NUfQW3RHSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUZ3HtcYEhdGmpYX7kJIJqdmSrbneg[I9u[WmwIHX4dJJme3OnZDDpckBpfW2jbjDI[ZAhTzJiY3XscJMh[29vdILhcpNn\WO2ZXSge4l1cCCJYXy0MWRDTCCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE4xPCEQvF2=	NHrqfYgyQTB3M{e3Oi=>
HeLa cells	Mm\qSpVv[3Srb36gZZN{[Xl?			NEL0TlhC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCuaXfhcoQh[mmwZHnu[{Bld22jaX6g[ZhxemW\|c3XkJIlvKGi3bXHuJGhmVGFiY3XscJMh[29vdILhcpNn\WO2ZXSge4l1cCCJYXy0MWRDTCCjc4Pld5Nm\CCjczD0doFve2O{aYD0bY9v[WxiYXP0bZZifGmxbjDifUBI[Wx2IILld5BwdnOnIHXs[Y1mdnRvZILpeoVvKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkCxOUDPxE1?	NXHZTGE3OTl{N{W5OlM>
COS1 cells	M3zp[GZ2dmO2aX;uJIF{e2G7			NHP5dWtC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHBRSVKpYX3tZUBz\WOncITvdkBmgHC{ZYPz[YQhcW5iYX\ybYNidiCpcnXlckBud26tZYmgR29UOSClZXzsd{Bkdy22cnHud4Zm[3SnZDD3bZRpKG[3c3XkJJlm[XO2IFfhcFQuTEKGIHL5JJRz[W6\|YXP0bZZifGmxbjDhd5NigSxiRVO1NF0xNjB{IN88US=>	Mnr1NVk2OzB4OEG=
U2OS cells	NVLNfW03TnWwY4Tpc44h[XO\|YYm=			M3zENmFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hJIV5eHKnc4Pl[EBqdiCXMl;TJINmdGy\|IHL5JIx2[2moZYLhd4UhfHKjboPhZ5RqfmG2aX;uJIF{e2G7LDDFR\|UxRTBwMEWg{txO	MkTPNVk2PzRyNU[=
HepG2 cells	M4Pk[mZ2dmO2aX;uJIF{e2G7			NWD1XGx2SWexbnnzeEBi[3Srdnn0fUBifCCJQVy0MZRi\2enZDDoeY1idiCSUFHS[4FudWFibHnnZY5lKGKrbnTpcoch\G:vYXnuJIV5eHKnc4Pl[EBqdiCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDy[YNmeHSxcjD0doFve2GldHn2ZZRqd25iYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvODN7IN88US=>	NFnGOJUyQTd5NUG2PS=>
HepG2 cells	MkfxSpVv[3Srb36gZZN{[Xl?			MX3B[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYTDlfJBz\XO\|ZXSgbY4hUGWyR{KgZ4VtdHNiYomgS2FNPCC2cnHud4FkfGm4YYTpc44h[XO\|YYmsJGVEPTB;MD6yNlMh\|ryP	NYj0cFMyOTl5OEO0OFQ>
COS7 cells	M376bmZ2dmO2aX;uJIF{e2G7			NEC3d49C\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJJJm[2:vYnnuZY51KFCSQWLnZY1u[TJiTFLEJIV5eHKnc4Pl[EBqdiCjZoLpZ4FvKGe{ZXXuJI1wdmuneTDDU3M4KGOnbHzzJINw\XiycnXzd4lv\yCJQVy0JIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UB1emGwc3HjeIl3[XSrb36gZZN{[XluIFXDOVA:OC5zIN88US=>	M1TWU\|IxOTN6N{[y
COS7 cells	MUPGeY5kfGmxbjDhd5NigQ>?			MWXB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIILlZ49u[mmwYX70JHBRSVKpYX3tZVEhVEKGIHX4dJJme3OnZDDpckBi\nKrY3HuJIdz\WWwIH3vcotmgSCFT2O3JINmdGy\|IHPv[ZhxemW\|c3nu[{BISUx2IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTD0doFve2GldHn2ZZRqd25iYYPzZZktKEWFNUC9NE4xOyEQvF2=	MmixNlAyOzh5NkK=
HEK cells	NWK4fGhzTnWwY4Tpc44h[XO\|YYm=			NGHCeYFC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJGdCVDRvdHHn[4VlKFCSQWLhcJBp[SClaHnt[ZJq[yC{ZXPldJRweiCneIDy[ZN{\WRiaX6gTGVMKGOnbHzzJIJ6KHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OD1zMD61PEDPxE1?	NF;IN5UzODJ7OUKxOC=>
HEK cells	MkSxSpVv[3Srb36gZZN{[Xl?			NGD5XVhC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJGdCVDRvdHHn[4VlKFCSQWLnZY1u[SClaHnt[ZJq[yC{ZXPldJRweiCneIDy[ZN{\WRiaX6gTGVMKGOnbHzzJIJ6KHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OD1yLkCzOUDPxE1?	NGXVTnMzODJ7OUKxOC=>
3T3L1 cells	NWjPTFJCTnWwY4Tpc44h[XO\|YYm=		NYjheodZPyCmYYnz	NIC3bYNKdmS3Y4Tpc44hd2ZiYXTpdI9o\W6nc3nzJIlvKG2xdYPlJFNVO0xzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIxqeGmmIHHjZ5VufWyjdHnvckBi\nSncjC3JIRigXNiYomgU4ltKHKnZDDPJJN1[WmwaX7n	M2TuWVIxPTJ5OU[5
CHO-K1 cells	MlSwSpVv[3Srb36gZZN{[Xl?			Mln5VIFzfGmjbDDh[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYT3MRmQh\XiycnXzd4VlKGmwIFPIU{1MOSClZXzsd{Bkdy22cnHud4Zm[3SnZDD3bZRpKEeDTESgZZN{\XO\|ZXSgZZMhdHWlaX\ldoF{\SCjY4Tpeol1gSCkeTD0doFve2GldHn2ZZRqd25iYYPzZZktKEWFNUC9NE4yKM7:TR?=	NVTFR21QOjB3Mke5Olk>
HEK293T cells	M1SxUmZ2dmO2aX;uJIF{e2G7	NX;2WpJsOSEQvF2=	NGLuU4czPCCqcoO=	M3zvZXBienSrYXygZYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDQVGFT\2GvbXGtUGJFKGW6cILld5Nm\CCrbjDISWszQTOWIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBz\WOncITvdkB1emGwc3HjeIl3[XSrb36gZZQhOSC3TTDh[pRmeiB{NDDodpMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5	NH2yVWQzOTB\|MEK2Ny=>
CV1 cells	NX;LOJhkTnWwY4Tpc44h[XO\|YYm=			M1L1bnRz[W6\|YXP0bZZifGmxbjDv[kBI[Wx2LX\1d4VlKGi3bXHuJHBRSVKpYX3tZUBFVkFiYnnu[Ilv\yCmb33hbY4h\XiycnXzd4VlKGmwIHHmdolk[W5iZ4Ll[Y4hdW:wa3X5JGNXOSClZXzsd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGVEPTB;MD6xJO69VQ>?	NYe3XYJtOjFzMUK3PFQ>
HEK293 cells	M4CwcWZ2dmO2aX;uJIF{e2G7		M2PHc\|E3KHSxIEKwJIhzew>?	NU\2d5k2XHKjboPhZ5RqfmG2aX;uJI9nKEejbESt[pV{\WRiaIXtZY4hWFCDUnfhcY1iKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNVYhfG9iMkCgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlA1OyEQvF2=	MlmxNlEyOjh4MEC=
HepG2 cells	MXLGeY5kfGmxbjDhd5NigQ>?	MVGxNEB2dW:uL1y=	M{XXfFI1KGi{cx?=	NUGxcXRkUW6lcnXhd4UhcW5iZ3z1Z49{\SClb37zeY1xfGmxbjDpckBpfW2jbjDI[ZBIOiClZXzsd{BifCBzMDD1cY9tN0xiYX\0[ZIhOjRiaILzJJJmdGG2aY\lJJRwKGOxboTyc4w>	M1rkSFIyOjV4N{S4
3T3L1 cell	NV7xeFFyTnWwY4Tpc44h[XO\|YYm=	NWfKXoFoOSC3TR?=		Ml\WTY5lfWO2aX;uJI9nKG2xdYPlJFNVO0xzIHPlcIwh\GmoZnXy[Y51cWG2aX;uJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHHjZ5VufWyjdHnvckBw\iCrboTyZYNmdGy3bHHyJIxqeGmmIHTyc5Bt\XRiYYSgNUB2VSCkeTDPbYwhemWmIF:gd5RicW6rbne=	MmTMNlE1ODFzMUi=
CV1 cells	M3LPOWZ2dmO2aX;uJIF{e2G7		MUK0NEBp	NHrR[pJC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHBRSVKpYX3tZU1NSkRiZYjwdoV{e2WmIHnuJGNXOSClZXzsd{Bkdy22cnHud4Zm[3SnZDD3bZRpKEejbESgZYZ1\XJiNECgbJJ{KGK7IHz1Z4ln\XKjc3WgZoF{\WRidILhcpNi[3SrdnH0bY9vKGG\|c3H5MEBGSzVyPUCuNUDPxE1?	NH61cHIzOTVzNUC2Ny=>
HepG2 cells	MVfGeY5kfGmxbjDhd5NigQ>?			NXfSPJVbSWexbnnzeEBi[3Srdnn0fUBifCCSUFHS[4FudWFicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJIh2dWGwIFjldGczKGOnbHzzJIJ6KFCSUlWtcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvODFizszN	NWnCdXJYOjF2OEK0OFY>
HepG2 cells	NFvoVIpHfW6ldHnvckBie3OjeR?=			NGTXd5FVemGwc3HjeIl3[XSrb36gc4YhcHWvYX6gVHBCWmejbX3hJIV5eHKnc4Pl[EBqdiCqdX3hckBJ\XCJMjDj[YxteyClbz30doFve2[nY4Tl[EB4cXSqIGDQVmU{NVSNLVz1Z{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGVEPTB;MD6wOUDPxE1?	MWGyNVQ2ODR4OB?=
COS7 cells	NUDXOHVbTnWwY4Tpc44h[XO\|YYm=			MnHjUY9lfWyjdHnvckBw\iCqdX3hckBRWEGUZ3HtcYEuVEKGIHX4dJJme3OnZDDpckBi\nKrY3HuJIdz\WWwIH3vcotmgSCFT2O3JINmdGy\|IHPvMZRz[W6\|ZnXjeIVlKHerdHigS4FtPCCjc4Pld5Nm\CCjczDhZ5RqfmG2aX;uJI9nKHS{YX7zZYN1cX[jdHnvckBi[3Srdnn0fUBjgSCudXPp[oVz[XOnIHHzd4F6NCCHQ{WwQVAvODR\|IN88US=>	NYDX[\|V4OjF6N{OwO\|A>
COS-1 cells	MXnGeY5kfGmxbjDhd5NigQ>?		Mn;ZNlQhcHK\|	MlHMRYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDQVGFT\2GvbXGgcIlo[W6mIHLpcoRqdmdiZH;tZYlvKGW6cILld5Nm\CCrbjDDU3MuOSClZXzsd{Bi\nSncjCyOEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nLXLhd4VlKGy3bXnuc41mfHKrYzDhcoFtgXOrczygSWM2OD1yLkC0PEDPxE1?	MmLKNlIxPTFyNUS=
COS1 cells	NVnQdnZUTnWwY4Tpc44h[XO\|YYm=		M4GxXFI1KGi{cx?=	NXH4eVRbXHKjboPhZ5RqfmG2aX;uJI9nKGi3bXHuJIZ2dGxibHXu[5RpKFCSQWLnZY1u[SCneIDy[ZN{\WRiaX6gR29UOSClZXzsd{Bkdy22cnHud4Zm[3SnZDD3bZRpKFK[UnHsdIhiKGGodHXyJFI1KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5zMjFOwG0>	MYOyNlE6PzN7Nh?=
MG-63 cells	MUTGeY5kfGmxbjDhd5NigQ>?			MYnB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYTDlfJBz\XO\|ZXSgbY4hVUdvNkOgZ4VtdHNiYomgdoVxd3K2ZYKg[4Vv\S2kYYPl[EB1emGwc3HjeIl3[XSrb36gZZN{[XluIFXDOVA:OC5yMUGg{txO	NFXEdIozOjJ{NU[0NS=>
COS1 cells	M4HkOWZ2dmO2aX;uJIF{e2G7			M1vWVGJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6ge4lt\CC2eYDlJHBRSVKpYX3tZUBNSkRiZYjwdoV{e2WmIHnuJGNQWzFiY3XscJMh[29vZYjwdoV{e2mwZzDHRWw1KGK7IIPjbY51cWyuYYTpc44heHKxeHntbZR6KGG\|c3H5	M3HYOVIzODdyNkC0
MG-63 cells	NUDUTo1iTnWwY4Tpc44h[XO\|YYm=		MlmzNlQhcHK\|	MlT1UY9lfWyjdHnvckBw\iCodXzsMYxmdme2aDDoeY1idiCyU1e1MYZ2e2WmIGDQRXJo[W2vYTDlfJBz\XO\|ZXSgbY4hVUdvNkOgZ4VtdHNiY3:t[ZhxemW\|c3nu[{BxT1ZvUEKtVHBTTSCjZoTldkAzPCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIJie2WmIITyZY5{[WO2aY\heIlwdiCjc4PhfUwhTUN3ME2wMlAyOSEQvF2=	NFvy[5YzOjd{N{S0PC=>
Ac2F cells	Mo\4SpVv[3Srb36gZZN{[Xl?	Mm\jNE4yKHSxIEGwJO69VQ>?	MXe2JIhzew>?	MXXB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBqdiC{YYSgRYMzTiClZXzsd{Bie3Onc4Pl[EBieyCudXPp[oVz[XOnIHHjeIl3cXS7IHH0JFAvOSC2bzCxNEB2VSCjZoTldkA3KGi{czDifUBz\XCxcoTldkBo\W6nIHHzd4F6	MVqyNlgyQTF7MB?=
293H DA cells	NV7NdYxUTnWwY4Tpc44h[XO\|YYm=		M3W5SFE3KGh?	NWP1S\|FYSWexbnnzeEBi[3Srdnn0fUBifCCSUFHS[4FudWFiTFLEJIlvKGi3bXHuJFI6O0hiRFGgZ4VtdHNiYX\0[ZIhOTZiaILzJIJ6KFSULV\SSXQh[WO2aY\heIlwdiC{ZYDvdpRmeiCjc4PhfUwhTUN3ME2wMlAxOjRizszN	MlTWNlI2QDJ7N{O=
3T3L1 cells	M3\FeGZ2dmO2aX;uJIF{e2G7	MoTRNVAhfU1?		M{PGbGlv[3KnYYPlJIlvKGGmaYDvcoVkfGmwIH3SUmEhdGW4ZXzzJIlvKFSQRnHsdIhiNWmwZIXj[YQhdW:3c3WgN3Q{VDFiY3XscJMheHKndILlZZRm\CCjdDCxNEB2VSCkZX\vdoUhXE6ILXHsdIhiKGOqYXzs[Y5o\SC{ZXzheIl3\SC2bzDjc451em:u	NXy4V29COjF6NUGwPFk>
HepG2 cells	Mlu4SpVv[3Srb36gZZN{[Xl?	NWXaRm9kOTBidV2=	NX3hZ4t2OjRiaB?=	MUnS[YR2[3Srb36gc4Yh\2y3Y3;z[UBkd26\|dX3weIlwdiCrbjDpcpN2dGmwLYLld4l{fGGwdDDoeY1idiCKZYDHNkBk\WyuczDheEAyOCC3TTDh[pRmeiB{NDDodpMh[nliZ3z1Z49{\SCxeHnkZZNmKG2ndHjv[EBqdiCycnXz[Y5k\SCxZjCyNk4zKG2PIH;mJIdtfWOxc3W=	NHW1SnUzOzB{NUK0OC=>
HepG2 cells	MVfGeY5kfGmxbjDhd5NigQ>?	M3iwcVExKHWP	MV2yOEBp	M360U3Jm\HWldHnvckBw\iCpbIXjc5NmKGOxboP1cZB1cW:wIHnuJIlve3WuaX6tdoV{cXO2YX70JIh2dWGwIFjldGczKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEK0JIhzeyCkeTDncJVkd3OnIH;4bYRie2VibXX0bI9lKGmwIIDy[ZNmdmOnIH;mJFAvOSC3TTDv[kBqdnO3bHnu	NULXTolnOjNyMkWyOFQ>
THP1 cells	MX;GeY5kfGmxbjDhd5NigQ>?	MmqzNVAxKHWP	NYPWV41zOyCqcoO=	M1PGdHRz[W6\|YXP0bZZifGmxbjDv[kBRWEGUZ3HtcYEhcW5iaIXtZY4hXEiSMTDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBNWFNvaX7keYNm\CCPQ2CxJI1TVkFiZYjwdoV{e2mxbjDheEAyODBidV2gdJJmcW6ldXLheIVlKG[xcjCzJIhzeyCycnnvdkB1dyCOUGOgZ4hidGynbnflJI1m[XO3cnXkJIFnfGW{IEG4JIhzeyCkeTDSWE1RS1JiYX7hcJl{cXNicnXsZZRqfmVidH:geY51emWjdHXkJINwdnS{b3y=	Mo\pNlI6OzR3M{e=
THP1 cells	NGS5Wm5HfW6ldHnvckBie3OjeR?=	MnfWNVAxKHWP	NX3YOWdtOyCqcoO=	NYW4PGJOXHKjboPhZ5RqfmG2aX;uJI9nKFCSQWLnZY1u[SCrbjDoeY1idiCWSGCxJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKEySUz3pcoR2[2WmIFnMOkBuWk6DIHX4dJJme3Orb36gZZQhOTByIIXNJJBz\WmwY4XiZZRm\CCob4KgN{BpenNicILpc5IhfG9iTGDTJINp[WyuZX7n[UBu\WG\|dYLl[EBi\nSncjCxPEBpenNiYomgVnQuWEOUIHHuZYx6e2m\|IILlcIF1cX[nIITvJJVvfHKnYYTl[EBkd262cn;s	NYnzVFlCOjJ7M{S1N\|c>
HepG2 cells	NIfsUItHfW6ldHnvckBie3OjeR?=			M{Lk[HRz[W6\|YXP0bZZifGmxbjDv[kBISUx2LX\1d4VlKFCSQWLnZY1u[SCuaXfhcoQh[mmwZHnu[{Bld22jaX6geJJidnOoZXP0[YQhcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvOSEQvF2=	M{PQeFIzQTN2NUO3
HepG2 cells	M33IZWZ2dmO2aX;uJIF{e2G7		NHTLRVAzOCCq	MkLERYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDHRWw1NW[3c3XkJHBRSVKpYX3tZUBtcWejbnSgZolv\GmwZzDkc41icW5iZYjwdoV{e2WmIHnuJGhmeEd{IHPlcIx{KGGodHXyJFIxKGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgeJJidnOjY4TpeoF1cW:wIHHzd4F6NCCHQ{WwQVAvODJizszN	MUGyNlA5OTl\|Mh?=
BL21 DE3 cells	M1zRTmZ2dmO2aX;uJIF{e2G7			MlnjSIl{eGyjY3Xt[Y51KG:oIGuzTH1zd3OrZ3zpeIF7d26nIH\yc40hVi22ZYLtbY5idCCKaYOteIFo\2WmIHj1cYFvKFCSQWLnZY1u[SCuaXfhcoQh[mmwZHnu[{Bld22jaX6g[ZhxemW\|c3XkJIlvKEW\|Y3jldolkcGmjIHPvcIkhSkx{MTDESVMh[2WubIOgZpkhe2OrboTpcIxifGmxbjDwdo95cW2rdImgZZN{[XluIFvpQVAvODd2IN88US=>	Ml7nNlIxQDF7M{K=
human L02 cells	MlvhSpVv[3Srb36gZZN{[Xl?			MoHHRYdwdmm\|dDDhZ5Rqfmm2eTDheEBRWEGUZ3HtcYEuVEKGIHX4dJJme3OnZDDpckBpfW2jbjDMNFIh[2WubIOgZ48u\XiycnXzd4lv\yCyR1yzMXNXPDBvR1HMOEBi\nSncjCyOEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHLhd4VlKHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OD1yLkmg{txO	NEjt[W4zOzF6NkOwOy=>
HepG2 cells	M2jScGZ2dmO2aX;uJIF{e2G7		NWjWem5HOjBiaB?=	MYrUdoFve2GldHn2ZZRqd25ib3[gS2FNPC2odYPl[EBpfW2jbjDQVGFT\2GvbXGgcIlo[W6mIHLpcoRqdmdiZH;tZYlvKGW6cILld5Nm\CCrbjDI[ZBIOiClZXzsd{Bi\nSncjCyNEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvODN7IN88US=>	NVW0fXlUOjNzN{GwOFU>
HEK293 cells	NV23cWdHTnWwY4Tpc44h[XO\|YYm=	NEXWS3QyOCEQvF2=		M3PMXXRz[W6\|YXP0bZZifGmxbjDv[kBRWEGUZ3HtcYEhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJINwNXS{YX7z[oVkfGWmIIfpeIghSVB{LWDQVmUh[XRiMUCgeW0h[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5	NH2xb3IzOzJ5M{WxPS=>
HEK293 cells	NHS1[olHfW6ldHnvckBie3OjeR?=			M4Pid2Fod26rc4SgZZQhcHWvYX6gVHBCWmejbX3hJGxDTCCneIDy[ZN{\WRiaX6gbJVu[W5iSFXLNlk{KGOnbHzzJINwfHKjboPm[YN1\WRid3n0bEBISUx2LVz1Z{Bie3Onc4Pl[EBieyC2cnHud4NzcXC2aX;uZYwh[WO2aY\heIlwdiCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE4xODRizszN	NF\KbpkzOzJ6Nke4Oy=>
HEK293 cells	MVfGeY5kfGmxbjDhd5NigQ>?		M4exeFI1KGh?	NXq4VFFsXHKjboPhZ5RqfmG2aX;uJI9nKEeDTESgSGJFNW[3c3XkJIh2dWGwIGDQRXJo[W2vYT3MRmQh\XiycnXzd4VlKGmwIFjFT\|I6OyClZXzsd{Bi\nSncjCyOEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvOSEQvF2=	NGLtRmUzOzJ7NEizNC=>
HEK293 cells	M{nxdWZ2dmO2aX;uJIF{e2G7		NIO2O2U1QCCqcoO=	MWrB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYTDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHPveJJidnOoZXP0[YQhf2m2aDDQVHJGgDRvVFutcJVkKGG\|c3Xzd4VlKGG\|IHHjeIl3[XSrb36gc4YhdHWlaX\ldoF{\SCjY4Tpeol1gSCvZXHzeZJm\CCjZoTldkA1QCCqcoOgZpkhfHKjboPhZ5RqfmG2aX;uJIF{e2G7LDDFR\|UxRTR\|LkexJO69VQ>?	NHrKTmYzOzJ4NUi0OC=>
HepG2 cells	MnTNSpVv[3Srb36gZZN{[Xl?			NEi2cllC\2:waYP0JIFkfGm4aYT5JIF1KEeDTESt[pV{\WRiUGDBVodidW2jIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJIh2dWGwIFjldGczKGOnbHzzJIJ6KHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OD1yLkCxJO69VQ>?	MlXzNlM2ODJ{MUK=
HepG2 cells	Ml\MSpVv[3Srb36gZZN{[Xl?			M2jKRWFod26rc4SgZYN1cX[rdImgZZQhT0GOND3meZNm\CCSUFHS[4FudWFiTUS2N2EhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKGi3bXHuJGhmeEd{IHPlcIx{KGK7IITyZY5{[WO2aY\heIlwdiCjc4PhfUwhTUN3ME2wMlAxOiEQvF2=	M1XiV\|I{PTB{MkGy
L6 cells	NGm5OJFHfW6ldHnvckBie3OjeR?=		NUPrc2Y4OjRiaILz	M3HUcmlv\HWldHnvckBw\iCpbIXjc5NmKHWydHHr[UBqdiC{YYSgUFYh[2WubIOgdJVte2WmIIfpeIghSzF2LXTlc5h6KGeudXPvd4Uh[W[2ZYKgNlQhcHK\|IHnuJJBz\XOnbnPlJI9nKGmwc4XsbY4tKEWFNUC9OE41QSEQvF2=	NXfZR5RTOjN7OUK4OlI>
L6 cells	NVXGV204TnWwY4Tpc44h[XO\|YYm=		MmDqNVYhcHK\|	NIHiTllKdmO{ZXHz[UBqdiB{LWuzTH0u\GWxeInncJVkd3OnIIXweIFs\SCrbjDyZZQhVDZiY3XscJMh[W[2ZYKgNVYhcHK\|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmdiYX7hcJl{cXNuIFXDOVA:PC56IN88US=>	M3;kflI1QDF\|N{O4
DU145 cells	MVPDfZRwfG:6aXPpeJkh[XO\|YYm=		Mn;0OFghcHK\|	NEjwVo9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDFR\|UxRTF4IN88US=>	M1vRNlI1QTl4MUSz
PC3 cells	NFrLeYJEgXSxdH;4bYNqfHliYYPzZZk>		MU[0PEBpenN?	Mlr4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEWFNUC9NlAvOyEQvF2=	MlXyNlQ6QTZzNEO=
MDA-MB-231 cells	M3TDOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlnINlQhcHK\|	MVTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFXDOVA:PS5{MzFOwG0>	MlizNlUzPzh{M{[=
HEK293 cells	MVXGeY5kfGmxbjDhd5NigQ>?			M2TUOGFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR\|UxRTBwMEGg{txO	MnfrNlU{ODV4OEi=
HepG2 cells	NUn6N4tiTnWwY4Tpc44h[XO\|YYm=		NXjOdHBuOjBiaILz	NIfOO2RVemGwc3HjeIl3[XSrb36gc4YhWFCDUjD0doFve2[nY4Tl[EBqdiCqdX3hckBJ\XCJMjDj[YxteyCjZoTldkAzOCCqcoOgZpkhWFCDUj3seYNq\mW{YYPlJIF{e2G7LDDFR\|UxRTFwNjFOwG0>	MW[yOVQ{PzNyNB?=
HEK293 cells	Ml;KSpVv[3Srb36gZZN{[Xl?		MnHINlQhcHK\|	NWDiTolPXHKjboPhZ5RqfmG2aX;uJI9nKFCSQWLnZY1u[SBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMhcW6ldXLheIVlKG[xcjCyOEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6	M4r4WlI2PDR{M{Ky
HepG2 cells	M{HM[WZ2dmO2aX;uJIF{e2G7			NUXhUYs4SWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBISUx2LWDQRXJo[W2vYTDsbYdidmRiYnnu[Ilv\yCmb33hbY4h\XiycnXzd4VlKGmwIHj1cYFvKEincFeyJINmdGy\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjB\|OTFOwG0>	MmrSNlU1PjJ{OEG=
HEK293 cells	NULMWXM6TnWwY4Tpc44h[XO\|YYm=		M3O1VlI1KGi{cx?=	M3rIVWFod26rc4SgZYN1cX[rdImgZZQhdW:3c3WgVHBCWmejbX3hJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZ48u\XiycnXzd4lv\yC5aYToJGdidDRicnXwc5J1\XJidnXjeI9zKGGodHXyJFI1KGi{czDifUBlfWGuLXz1Z4ln\XKjc3WgdoVxd3K2ZYKgZZN{[XluIFXDOVA:OC5yMzFOwG0>	Mn\0NlQ6PTV6OEm=
HepG2 cells	Ml3RSpVv[3Srb36gZZN{[Xl?		MU[yNEBpenN?	NWXXcHlVSWexbnnzeEBi[3Srdnn0fUBifCCJQVy0MWRPSSCkaX7kbY5oKGSxbXHpckBnfXOnZDDoeY1idiCSUFHS[4FudWFibHnnZY5lKGKrbnTpcoch\G:vYXnuJIV5eHKnc4Pl[EBqdiCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDy[YNmeHSxcjD0doFve2GldHn2ZZRqd25iaX7jeYJifGWmIH\vdkAzOCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR\|UxRTBwMESg{txO	MnjPNlU1QTdzM{K=
HepaR cells	MonTSpVv[3Srb36gZZN{[Xl?		MmjwNUBl[Xl?	NHP5VJJC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCrbjDoeY1idiCKZYDhVkBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCKTVfDV\|Ih\2WwZTDlfJBz\XO\|aX;uJIF1KDFidV2gbY5kfWKjdHXkJIZweiBzIHThfUBjgSCzdXHueIl1[XSrdnWgVGNTKG2ndHjv[EBz\WyjdHn2[UB1dyC3boTy[YF1\WRiY3;ueJJwdA>?	NYjZcldWOjV2OUexN\|I>
HepaR cells	MUXGeY5kfGmxbjDhd5NigQ>?	MUKxJJVO	NWDaZ457OSCmYYm=	MonsRYdwdmm\|dDDhZ5Rqfmm2eTDheEBRWEGUZ3HtcYEhcW5iaIXtZY4hUGWyYWKgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hSU6JUGTMOEBo\W6nIHX4dJJme3Orb36gZZQhOSC3TTDpcoN2[mG2ZXSg[o9zKDFiZHH5JIJ6KHG3YX70bZRifGm4ZTDQR3IhdWW2aH;kJJJmdGG2aY\lJJRwKHWwdILlZZRm\CClb370do9t	MkTMNlU1QTdzM{K=
HepaR cells	MXHGeY5kfGmxbjDhd5NigQ>?	NHTUNVkyKHWP	MX2xJIRigQ>?	MmDBRYdwdmm\|dDDhZ5Rqfmm2eTDheEBRWEGUZ3HtcYEhcW5iaIXtZY4hUGWyYWKgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hTkGEUEGg[4Vv\SCneIDy[ZN{cW:wIHH0JFEhfU1iaX7jeYJifGWmIH\vdkAyKGSjeTDifUByfWGwdHn0ZZRqfmViUFPSJI1mfGixZDDy[YxifGm4ZTD0c{B2dnS{ZXH0[YQh[2:wdILvcC=>	NEXCS5MzPTR7N{GzNi=>
HEK293 cells	MU\GeY5kfGmxbjDhd5NigQ>?	Mm\tNVAh\|ryP	NWr0fVNzOjRiaILz	NFHn[WhVemGwc3HjeIl3[XSrb36gc4YhWFCDUj3nZY1u[SBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[XRiMUCgeW0h[W[2ZYKgNlQhcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>?	Ml3RNlQ5QTByOUC=
C2C12 cells	M1X4N2Z2dmO2aX;uJIF{e2G7	MWqzNEDPxE1?	NX3GTHNZOiCq	NHjsdpNKdmS3Y4Tpc44hd2ZiMj3k[Y95gS2dM1jdMYdtfWOxc3WgeZB1[WunIHnuJI1wfXOnIFOyR\|EzKGOnbHzzJIF1KDNyIIXNJIFnfGW{IEKgbJJ{KGK7IHzpdZVq\CC\|Y3nueIltdGG2aX;uJINwfW62aX7nJIFv[Wy7c3nz	M3r6cVI2QDN3NUO3
MCF7 cells	NY\yXJVOTnWwY4Tpc44h[XO\|YYm=		M3vhR\|E3KGh?	M1vKUGFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hJJRz[W6\|ZnXjeIVlKGmwIHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhOTZiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkC4O{DPxE1?	NHP1UFUzPjJ{NkS5NC=>
HEK293 cells	MljPSpVv[3Srb36gZZN{[Xl?	MWqxNEDPxE1?	Mki4NlQhcA>?	NHfqc3VC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[XO\|ZYPz[YQh[XNicnXj[ZB1d3JidILhcpNi[3SrdnH0bY9vKGG2IEGwJJVOKGmwY4XiZZRm\CCob4KgNlQhcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>?	MYGyOlM5PDJ6Nh?=

... Click to View More Cell Line Experimental Data

Protocol

References

Solubility (25°C)

In vitro	DMSO	35 mg/mL (198.67 mM)
	Ethanol	35 mg/mL (198.67 mM)
	Water	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download 4-Methylumbelliferone (4-MU) SDF

Molecular Weight	176.17
Formula	C₁₀H₈O₃
CAS No.	90-33-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=CC(=O)OC2=C1C=CC(=C2)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Related Others Products

Telaglenastat (CB-839) ^New

Telaglenastat (CB-839) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. CB-839(Telaglenastat) inudces autophagy and has antitumor activity. Phase 1.
Setanaxib (GKT137831) ^New

Setanaxib (GKT137831) is a potent, dual NADPH oxidase NOX1/NOX4 inhibitor with Ki of 110 nM and 140 nM, respectively. Treatment with GKT137831 suppresses reactive oxygen species (ROS) production. GKT137831 partly inhibits ferroptosis.
LB-100 ^New

LB-100 is a water soluble protein phosphatase 2A (PP2A) inhibitor with IC50s of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells.
Puromycin 2HCl

Puromycin 2HCl is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.
Cyclosporin A

Cyclosporin A (Cyclosporine A) is an immunosuppressive agent, binds to the cyclophilin and then inhibits calcineurin with IC50 of 7 nM in a cell-free assay, widely used in organ transplantation to prevent rejection.
Cyclophosphamide Monohydrate

Cyclophosphamide Monohydrate is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA, shown to crosslink DNA, causing strand breakage and inducing mutations.
Ganciclovir

Ganciclovir (RS-21592, BW-759) is an antiviral drug for feline herpesvirus type-1 with IC50 of 5.2 μM in a cell-free assay.
Calcitriol

Calcitriol (RO215535, Topitriol) is a nonselective vitamin D receptor activator/agonist(VDRA), exhibiting a 10-fold higher vitamin D receptor (VDR) binding affinity(IC50=0.4 nM) than the selective VDRA paricalcitol.
Ribavirin

Ribavirin (NSC-163039, ICN-1229, RTCA, Tribavirin), a synthetic guanosine analogue, possesses a broad spectrum of activity against DNA and RNA viruses.
BAPTA-AM

BAPTA-AM is a selective, membrane-permeable calcium chelator.

Choose Your Country or Region

By Signaling Pathways

By product type

4-Methylumbelliferone (4-MU)